Seasoned healthcare executive specializing in business acceleration brings strategic experience to telehealth company’s board of directors
AristaMD, a leading digital health company that provides proprietary eConsult solutions that connect primary care providers (PCPs) with timely, documented specialist insights, announced today the addition of Ann Barnes, CEO of Intelligent Medical Objects (IMO), to its board of directors. Barnes brings over 30 years of experience achieving sustained revenue, profit and business growth within start-ups, Fortune 100 and mid-sized private equity backed companies, with a unique combination of experience in the healthcare, financial and technology industries.
Barnes joined IMO, the leading provider of medical terminology content and workflow software, two years ago. As CEO, she is responsible for development and successful execution of IMO’s strategy, including translating that strategy into a tactical plan and leading the organization to achieving and exceeding metrics-based objectives. Prior to joining IMO, Barnes served as CEO at MedData, a leading provider of technology enabled services to drive financial success for healthcare partners while creating a positive patient experience. During her time at MedData, Barnes successfully achieved revenue and EBITDA growth targets in excess of 30% year over year, spearheading and overseeing the company’s sale to publicly held MEDNAX.
“We are honored to welcome Ann to our board of directors,” said Brooke LeVasseur, CEO of AristaMD. “Her track record speaks for itself. She is the rare combination of innovative entrepreneur and growth-oriented operator who knows how to build high-performing teams and exceed audacious goals. We know Ann will provide valuable perspectives and measurable impact to the company.”
With the strategic addition of Barnes to the board of directors at AristaMD, the company is further positioned for continued and rapid growth that includes a wide range of product and process improvements that have significantly enhanced AristaMD’s capabilities and scalability. These efforts were the necessary groundwork that led to the company successfully completing its Series B funding round at $24 million in early 2020.
“It’s already been a landmark year for AristaMD and I look forward to helping further accelerate commercial growth and cultivate ideas that progress the company’s mission,” said Barnes. “Technology can, and should, facilitate collaboration between healthcare providers to expedite time to treatment, decrease costs and drive better patient outcomes. AristaMD is doing important work in these areas and I’m honored to serve on its board of directors.”
Barnes was referred to AristaMD through Break into the Boardroom (BiB), an initiative run by Oxeon Partners and Deerfield that promotes greater representation of female healthcare executives in the Boardroom.
